the sorts [2%),:<3%), arthralgia ( 1%), back pain ( 1%) Ophthalmic: Dry eye syndrome (2%), visual disturbance ( 1%) Respiratory: Flu-like symptoms (1% to 3%), bronchitis ( 1%), pharyngitis ( 1%), rhinitis ( 1%), sinusitis ( 1%) Postmarketing and/or case reports (Limited to important or life-threatening): Anaphylaxis, angioedema, confusion, erythema multiforme, granuloma (annulare), hallucination, hypersensitivity reaction Warnings/Precautions Concerns related to adverse effects: Angioedema: Angioedema involving the face, lips, tongue, and/or larynx have been reported; some cases have occurred after the first dose. May be life-threatening. Immediately discontinue and institute supportive care if tongue, hypopharynx, or larynx is involved. CNS effects: CNS effects have been reported (eg, headache, confusion, hallucinations, somnolence); monitor for CNS effects, particularly at treatment initiation or dose increase; reduce dose or discontinue if necessary. May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise. Disease-related concerns: Bladder flow obstruction: Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention. Gastrointestinal disease: Use with caution in patients with decreased GI motility (severe constipation, ulcerative colitis) or GI obstructive disorders ( pyloric stenosis); may increase the risk of gastric retention. Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma. Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment required in moderate hepatic impairment (Child-Pugh class B). Not recommended for use in severe hepatic impairment (Child-Pugh class C). Myasthenia gravis: Use with caution in patients with myasthenia gravis. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Monitoring Parameters Anticholinergic effects (eg, CNS effects [headache, confusion, hallucinations, somnolence], fixed and dilated pupils, blurred vision, tremors, dry skin); hepatic function. Pregnancy Risk Factor C Pregnancy Considerations Adverse events have been observed in animal reproduction studies. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience heartburn or dry mouth. Have patient report immediately to prescriber signs of a urinary tract infection (hematuria, burning or painful urination, polyuria, fever, lower abdominal pain, or pelvic pain), severe headache, dizziness, passing out, confusion, hallucinations, severe fatigue, severe constipation, severe abdominal pain, urinary retention, vision changes, lack of sweating, severe nausea, severe vomiting, or loss of strength and energy (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about darifenacin Side Effects During Pregnancy Dosage Information Drug Images Drug Interactions Support Group Pricing & Coupons En Español 19 Reviews Add your own review/rating Drug class: urinary antispasmodics Consumer resources Darifenacin Darifenacin (Advanced Reading) Professional resources Darifenacin Hydrobromide (AHFS Monograph) Darifenacin (FDA) Other brands: Enablex Related treatment guides Overactive Bladder Urinary Incontinence> ] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Darifenacin Rating 19 User Reviews 6.3 /10 19 User Reviews 6.3 Rate it! Manufacturers Par Pharmaceutical, Inc. Teva Pharmaceuticals USA, Inc. Torrent Pharmaceuticals Limited Aurobindo Pharma Limited Jubilant Cadista Pharmaceuticals Inc. Macleods Pharmaceuticals Limited More... Drug Class Urinary antispasmodics Related Drugs urinary antispasmodics oxybutynin , Myrbetriq , VESIcare , Ditropan , tolterodine , Toviaz Overactive Bladder oxybutynin , Myrbetriq , VESIcare , Ditropan , tolterodine , Toviaz , solifenacin , mirabegron , Detrol , Botox , trospium , Enablex , More... Urinary Incontinence oxybutynin , VESIcare , Ditropan , tolterodine , Toviaz , solifenacin , Detrol , trospium , Enablex , Ditropan XL , fesoterodine , Detrol LA , More... Darifenacin Images Darifenacin systemic 7.5 mg (base) (C170 ) View all images from time to time
inexpensive Darifenacin thinking of
EmoticonEmoticon